造血干细胞移植在神经母细胞瘤应用的系统评价
|
摘要
目的:本研究旨在应用Meta分析(meta-analysis)的方法对国内外已发表的有关造血干细胞移植治疗儿童神经母细胞瘤的长期疗效和安全性的文献进行综合分析,为晚期高危神经母细胞瘤患儿治疗提供循证医学证据。
方法:检索Cochrane图书馆、Pubmed、ScienceDirect、Embase、中国生物医学文献光盘数据库,中国期刊全文数据库和中国维普数据库维普及万方数据库,检索年限为1974年1月至2010年1月,收集已公开发表的有关造血干细胞移植治疗神经母细胞瘤的随机对照研究(RCT),按Meta分析的要求对检索到的原始文献进行质量评估,对符合条件的研究结果应用Revman 5.0软件进行Meta分析。
结果:符合纳入标准的共5篇文献,涉及患儿共743人。纳入5年无病生存率比较的文献5篇,样本量743例,合并OR=2.13,95%可信区间为[1.5,3.01];纳入5年总生存率比较的文献5篇,合并OR=1.79,95%可信区间为[1.14,2.80];纳入治疗相关性死亡分析的文献4篇,样本量713例,合并OR=4.39,95%可信区间为[2.26,8.51];纳入第二肿瘤发生分析的文献3篇,样本量554例,合并OR=0.84,95%可信区间为[0.18,3.88]。敏感性分析显示研究结果具有良好的可靠性。
结论:1、化疗、手术、放疗联合造血干细胞移植优于持续化疗,能改善高危神经母细胞瘤患儿长期生存。2、造血干细胞移植的治疗相关死亡率高于化疗组。3、移植第二肿瘤发生无明显关系。该方法是治疗高危神经母细胞瘤患儿的理想途径,但安全性有待进一步验证。
Objective:In the current study, the author conducted a meta-analysis of the published literatures to evaluate the efficacy and safety of autologous hematopoietic stem cells transplantation treatment of high-risk neuroblastoma in children.
Methods:The Cochrane library, Pubmed, Embase, ScienceDirect, CNKI,CBM,cqvip and wanfang data were searched from time when the database were established to January 2010.Reports on controlled trials on treating NB in children with AHSCT were collected .The methodology quality of included RCTs was assessed by the revised Jadad-score (including randomization , allocation concealment ,blinding method and withdraw) Meta–analysis of homogenous trials was manged by using revman 5.0.
Results : Five studies were eligible for the Meta analysis, which enrolled a total of 743 children . Meta-analysis based on include RCTs showed the following results.There were 5 studies refer to 5-EFS and 5-OS.OR=2.13, 95%CI [1.50,3.01], OR=1.79, 95%CI [1.14,2.80]. Treat-related death were involved in 4 records OR= 4.39,95%CI [2.26 , 8.51]. There were 3 studies refer to the incidence of second malignant neoplasms ,OR=0.84,95% CI [0.18 , 3.88]. The sensitivity analyse shows the results were reliable.
Conclusions: This meta-analysis showed that the treatment including chemotherapy,surgery, radiotherapy combining AHSCT is better than persistent chemotherapy,which could impove the long term efficacy in high-risk neuroblastoma in children . The related-death rate was higher than patient with chemotherapy . But there is no difference in incidence of second malignant neoplasms . AHSCT could be one of the ideal therapy for high-risk neuroblastoma .The safety of AHSCT needs more research.
方法:检索Cochrane图书馆、Pubmed、ScienceDirect、Embase、中国生物医学文献光盘数据库,中国期刊全文数据库和中国维普数据库维普及万方数据库,检索年限为1974年1月至2010年1月,收集已公开发表的有关造血干细胞移植治疗神经母细胞瘤的随机对照研究(RCT),按Meta分析的要求对检索到的原始文献进行质量评估,对符合条件的研究结果应用Revman 5.0软件进行Meta分析。
结果:符合纳入标准的共5篇文献,涉及患儿共743人。纳入5年无病生存率比较的文献5篇,样本量743例,合并OR=2.13,95%可信区间为[1.5,3.01];纳入5年总生存率比较的文献5篇,合并OR=1.79,95%可信区间为[1.14,2.80];纳入治疗相关性死亡分析的文献4篇,样本量713例,合并OR=4.39,95%可信区间为[2.26,8.51];纳入第二肿瘤发生分析的文献3篇,样本量554例,合并OR=0.84,95%可信区间为[0.18,3.88]。敏感性分析显示研究结果具有良好的可靠性。
结论:1、化疗、手术、放疗联合造血干细胞移植优于持续化疗,能改善高危神经母细胞瘤患儿长期生存。2、造血干细胞移植的治疗相关死亡率高于化疗组。3、移植第二肿瘤发生无明显关系。该方法是治疗高危神经母细胞瘤患儿的理想途径,但安全性有待进一步验证。
Objective:In the current study, the author conducted a meta-analysis of the published literatures to evaluate the efficacy and safety of autologous hematopoietic stem cells transplantation treatment of high-risk neuroblastoma in children.
Methods:The Cochrane library, Pubmed, Embase, ScienceDirect, CNKI,CBM,cqvip and wanfang data were searched from time when the database were established to January 2010.Reports on controlled trials on treating NB in children with AHSCT were collected .The methodology quality of included RCTs was assessed by the revised Jadad-score (including randomization , allocation concealment ,blinding method and withdraw) Meta–analysis of homogenous trials was manged by using revman 5.0.
Results : Five studies were eligible for the Meta analysis, which enrolled a total of 743 children . Meta-analysis based on include RCTs showed the following results.There were 5 studies refer to 5-EFS and 5-OS.OR=2.13, 95%CI [1.50,3.01], OR=1.79, 95%CI [1.14,2.80]. Treat-related death were involved in 4 records OR= 4.39,95%CI [2.26 , 8.51]. There were 3 studies refer to the incidence of second malignant neoplasms ,OR=0.84,95% CI [0.18 , 3.88]. The sensitivity analyse shows the results were reliable.
Conclusions: This meta-analysis showed that the treatment including chemotherapy,surgery, radiotherapy combining AHSCT is better than persistent chemotherapy,which could impove the long term efficacy in high-risk neuroblastoma in children . The related-death rate was higher than patient with chemotherapy . But there is no difference in incidence of second malignant neoplasms . AHSCT could be one of the ideal therapy for high-risk neuroblastoma .The safety of AHSCT needs more research.
引文
1 Cotterill SJ,Pearson AD,Pritchard J,et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group′Survey′1982-1992, Eur J Cancer,2000,36(7):901-908
2 Zage PE, Kletzel M, Murray K, et al. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma:a report from the Children′s Oncology Group, Pediatr Blood Cancer, 2008,51(6):747-753
3 Masue Imaizumi, Arata Watanabe,et al. Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation:a retrospective analysis from the Tohoku Neuroblastoma Study Group, Tohoku J Exp, Med, 2001,19(5):73-83
4 Matthay KK,Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid, Children′s Cancer Group, N Engl J Med, 1999, 341(16):1165-1173
5王家良,主编,循证医学,第2版,北京:人民卫生出版社,2006, 81, 84-85, 87-88, 89-90
6詹思延,如何报告系统综述和Meta分析,药物不良反应杂志,2006,8 (4):312-14
7 Castel V, García-Miguel P, Canete A, et al. Prospective evaluation ofthe International Neuroblastoma Staging System (NISS) and the International Neuroblastoma Response Criteria (NIRC) in a multicentre setting, Eur J Cancer,1999 ,35(4):606-611
8 Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in Meta-analyses , BMJ, 2003, 327: 557-60
9 Pritchard J,Cotterill SJ, Germond SM, et al. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomized trial (ENSG1) by the European Neuroblastoma Study Group, Pediatr BloodCancer , 2005,4(4):348–52
10 Berthold F, Boos J, Burdach S, et a1. Myeloablative megatherapy With autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial , lancet Oncol, 2005,6:649–58
11 Daniel O Stram,Katherine K. Matthay, et a1. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma:A report of two concurrent children cancer group studies, journal of clinical oncology ,1996,14(9): 2417-2424
12 Suster JJ,The role of autologous bone marrow transplantation in advanced neuroblastoma, J Clin Oncol ,1996,14(24):13–14
13 Chard J,“Megatherapy”for advanced neuroblastoma—rationale and role. Eur J Cancer,1995, 31A:134–36
14刘关键,吴泰相,康德英,Meta-分析中的统计学过程,中国临床康复,2003,7(4):538-539
15李立明,黄悦勤等,临床流行病学(第一版),人民卫生出版社,2002:279-281
1 Cheung NK, Heller G, Chemotherapy dose intensity correlates strongly with response, median survival and median progression free survival in metastatic neuroblastoma, J Clin Oncol ,1991,9,1050-1058
2 Pearson AD, Pinkerton CR, Lewis IJ,et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma:a randomised trial, Lancet Oncol, 2008,9(3):247-256
3 Pinkerton CR , Blanc Vincent MP, Bergeron C, et al.Induction chemotherapy in metastatic neuroblastoma-does dose influence response?A critical review of published data standards,options and recommendations (SOR)project of the national federation of french cancer centres(FNCLCC), Eur J Cancer ,2000,36:1808-15
4 Sung KW,Lee SH,Yoo KH, et al Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma, Bone Marrow Transplant,2007,40(1):37-45
5 Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry, J Clin Oncol, 1998,16(3):953-965
6 Brian H,Kushner Q , Michael P, et al . Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children With High-Risk Neuroblastoma,Journal of clinical oncology original report, 2004,22(1):146-156
7 Nitschke R,Parkhurst J,Sullivan J,et al. Topotecan in pediatric patients with recurrent and progressive solid tumors:A Pediatric Oncology Group phaseⅡstudy , J Pediatr Hematol Oncol,1998,20(4):315-318
8 Saylors RL ,Stine KC,Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phaseⅡstudy, J Clin Oncol, 2001,19(15):3463-3469
9 Athale UH,Stewart C, Kuttesch JF, et al. PhaseⅠstudy of combination topotecan and carboplatin in pediatric solid tumors, J Clin Oncol, 2002, 20(1):88-95
10高解春,金百祥,Ⅲ、Ⅳ期神经母细胞瘤的外科处理,中华小儿外科杂志,1995,16:70
11高解春,小儿晚期恶性肿瘤延期和二次手术的指征和时机,中华小儿外科杂志,1995,16:295
12江启俊,外科治疗神经母细胞瘤的世纪回顾及展望,中华小儿外科杂志,2000,21:137
13 Meller S, Targeted radiotherapy for neuroblastoma, Arch Dis Child, 1997,77(5):389-391
14 Sehmidt M, Simon T, Hero B, et a1.Is there a benefit of131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma?A retrospective evaluation of the German Neuroblastoma Trial NB97 and implications for the German Neuroblastoma Trim, NB 2004 Nuklearmedizin, 2006,45(4):145-151
15 Matthay KK, Tan JC, Villahlanca JG, et a1.PhaseⅠdose escalation ofIodine-131I-metaiodobenzylguanidine with myeloablative chemother- apy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study, J Clin Oncol , 2006,24(3):500-506
16 Garaventa A, Gambini C, Villavecchia Gm ,et al. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodohanzylguanidine, Cancer , 2003,97(5):1332-1338
17 Weiss B,Vora A, Huberty J, et a1. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma, J Pediatr Hematol Oncol, 2003,25(7):543-547
18 Osenga KL, Hank JA, Albertini MR,et a1. A phase I clinical trial of the hul4.18-IL2(EMD 273063)as a treatment for chil dren with refractory or recurrent neuroblastoma and melanoma:a study of the Children’s Oncology Group, Clin Cancer Res , 2006,12(6):1750-1759
19 Gilman AI, Matthay KK,et a1. Phase I study of chl4.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue:a report from the Children’s Oncology Group, J Clin Oncol, 2009, 27(1):85-91
20 Verdeguer A, Munoz A, Canete A, et al . Long-term results of high-dose chemotherapy and autologousstem cell rescue forhigh-risk neuroblastoma patients: a report of the Spanish working party for BMT in children (Getmon) ,Pediatr Hematol Onenl , 2004, 21:495-504
21 Berthold F, Boos J, Burdach S,et a1.Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance hemotherapy as consolidation treatment in patients with high-risk neuroblastorna : a randomised controlled trial, theLancet Oncol, 2005,6:649-658
22 Philip T, Ladenstein R, Lasset C, et al 1070 myeloablative megatherapy procedurea followed by stem cell rescue for neuroblastoma:17 years of European experience and conclusions.European Group for Blood andMarrow Transplant Registry Solid Tumour Working Party, Eur J Cancer,1997, 33:2130-2135
23 Zage PE, Kletzel M, Murray K, et al. Outcomes of the POG 9340/ 9341/9342 trials for children with high-risk neuroblastoma: a report from the Children′s Oncology Group, Pediatr Blood Cancer, 2008,51(6):747-753
24 Imaizum iM, W atanabe A, Kikuta A, et al. Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation:a retrospective analysis from the Tohoku Neuroblastoma Study Group, Tohoku J Exp Med, 2001,195(2):73-83
25 Stram Do,Matthay KK O, Leary M, et al.Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma:a report of two concurrent Children's Cancer Group studies,J CIin Oncol, 1996,14:2417-2426
26 Ladenstein R, Lasset C,Hartmann O,et a1. Comparison of auto versus allografting as consolidation of primary treatments in advanced neurob- lastoma over one year of age at diagnosis: report from theEuropean Groupfor Bone MarrowTransplantation, Bone MarrowTransplant,1994,14:37-46
27 Samuels HL, Bitran JD, High-dose intravenous melphalan:a review, J Clin Oncol, 1995, 13:1786 -1799
28 Donovan J,Temel J, Zuckel'manA, et al. CD34 selectionas a stem cell purging strategy for neuroblastoma: preclinical and clinical studies, Med Pediatr Oncol,2000,35:677-682
29 Handgretinger R,Larlg P,Ihm K, et al. Isolation and transplantation of highly purified autologous peripheral CD34(+)progenitor cells:purging efficacy, hematopoietie reconstitution and long-term outcome in children with high-risk neuroblastoma,Marrow Transplant, 2002,29:731-736
30陈静,沈小钰,汤静燕等,儿童晚期神经母细胞瘤自身造血干细胞移植疗效评估,中国循证儿科杂志, 2009,4( 2)118-122
31 George RE, Li S,Medeiros-Nancarrow C,et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell supported transplantation: long-term survival update, J ClinOnco, 2006,24:2891-2896
32 yon AIlmen ,DtGrupp S,Diller L, et a1. Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence and transplant, J Pediatr surg , 2005, 40:936-941
33 Jing w ,Orentas RJ, Johnson BD, Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem eell trapsplantation using a hovel mouse tumor vaccine, Biol Blood MarrowTransplant, 2007,13:277-292
34 Toren A, Nagler A, Rozenfeld-Granot G, et a1.Amplification of immunologieal functions by subeutaneoua injection of intermediate dose interleukin-2 for 2 years after autologous stem cell transplantation in children with stage IV neumblastoma.Transplantation, 2000, 70:1 100-1 104
35 Wassberg E, Christofferson R.Angiostatic treatment of neuroblastoma,Eur J Cancer, 1997, 33:2-20
36 Frost JD, Hank JA, Reaman GH,et al. A phase I/BI trial of murine monoclonal anti-GD2 antibody plus interleukin-2 in children with refractory neuroblastoma:A report of the Children′s Cancer Group, Cancer,1997,80(2):317-333
37 Niethammer D, Hemdgnetinger. Clinical strategies for the treatment of neuroblastoma, Eur J Cancer,1995,31:568 -571
38 Valteau-Couanet D, Leboulaire C,Maincent K, et a1.Dendritie cells for NK/ LAK activation:rationale for multicellular immlunotherapy in neurob-lastoma patients, Blood, 2002,100:255-256
39 Reynolds CP, Detection and treatment of minimal residual disease in high-risk neuroblastoma, Pediatr Transplant, 2004, 8:56-66
40 Katzenstein HM, Rademaker AW, Senger C, et al Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden,Clin Cancer Res,1999,5(12):4273-4278
41 Shusterman S,Grupp SA,Barr R,et al The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth,especially in the setting of subclinical disease, Clin Cancer Res,2001,7(4):977-984
42 Kohler JA, Imeson J, Ellershaw C, et al. A randomized trial of 13-cis retinoic acid in childrenwith advanced neuroblastoma after high-dose therapy, Br J Cancer , 2000, 83:1124-1127
43 Bown N, Lastowska M, Cotterill S,et al. 17q gain in neuroblastoma predicts adverse clinical outcome.U.K Cancer Cytogenetics Group and the U.K.Children’s Cancer Study Group. Med Pediatr Oncol, 2001, 36(1)14-19
44 Mihaila D, Ap rodu G, Ionescu C, et al. Limitations in the histopathologic diagnosis and prognosis of neuroblastoma,RevMed ChirSoc Med Nat Lasi, 2003,107(4):834-840
45 Zumkeller W, Schwab M, Insulin-like growth factor system in neuroblastoma tumorigenesis and apoptosis perspectives, Horm Metab Res, 1999, 31:138 -141
46 Donfrancesco A , Deb G , DE Sl, et al. Role of deferoxamine in tumor therapy, Acta Haenatol,1996,95:66 -69
2 Zage PE, Kletzel M, Murray K, et al. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma:a report from the Children′s Oncology Group, Pediatr Blood Cancer, 2008,51(6):747-753
3 Masue Imaizumi, Arata Watanabe,et al. Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation:a retrospective analysis from the Tohoku Neuroblastoma Study Group, Tohoku J Exp, Med, 2001,19(5):73-83
4 Matthay KK,Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid, Children′s Cancer Group, N Engl J Med, 1999, 341(16):1165-1173
5王家良,主编,循证医学,第2版,北京:人民卫生出版社,2006, 81, 84-85, 87-88, 89-90
6詹思延,如何报告系统综述和Meta分析,药物不良反应杂志,2006,8 (4):312-14
7 Castel V, García-Miguel P, Canete A, et al. Prospective evaluation ofthe International Neuroblastoma Staging System (NISS) and the International Neuroblastoma Response Criteria (NIRC) in a multicentre setting, Eur J Cancer,1999 ,35(4):606-611
8 Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in Meta-analyses , BMJ, 2003, 327: 557-60
9 Pritchard J,Cotterill SJ, Germond SM, et al. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomized trial (ENSG1) by the European Neuroblastoma Study Group, Pediatr BloodCancer , 2005,4(4):348–52
10 Berthold F, Boos J, Burdach S, et a1. Myeloablative megatherapy With autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial , lancet Oncol, 2005,6:649–58
11 Daniel O Stram,Katherine K. Matthay, et a1. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma:A report of two concurrent children cancer group studies, journal of clinical oncology ,1996,14(9): 2417-2424
12 Suster JJ,The role of autologous bone marrow transplantation in advanced neuroblastoma, J Clin Oncol ,1996,14(24):13–14
13 Chard J,“Megatherapy”for advanced neuroblastoma—rationale and role. Eur J Cancer,1995, 31A:134–36
14刘关键,吴泰相,康德英,Meta-分析中的统计学过程,中国临床康复,2003,7(4):538-539
15李立明,黄悦勤等,临床流行病学(第一版),人民卫生出版社,2002:279-281
1 Cheung NK, Heller G, Chemotherapy dose intensity correlates strongly with response, median survival and median progression free survival in metastatic neuroblastoma, J Clin Oncol ,1991,9,1050-1058
2 Pearson AD, Pinkerton CR, Lewis IJ,et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma:a randomised trial, Lancet Oncol, 2008,9(3):247-256
3 Pinkerton CR , Blanc Vincent MP, Bergeron C, et al.Induction chemotherapy in metastatic neuroblastoma-does dose influence response?A critical review of published data standards,options and recommendations (SOR)project of the national federation of french cancer centres(FNCLCC), Eur J Cancer ,2000,36:1808-15
4 Sung KW,Lee SH,Yoo KH, et al Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma, Bone Marrow Transplant,2007,40(1):37-45
5 Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry, J Clin Oncol, 1998,16(3):953-965
6 Brian H,Kushner Q , Michael P, et al . Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children With High-Risk Neuroblastoma,Journal of clinical oncology original report, 2004,22(1):146-156
7 Nitschke R,Parkhurst J,Sullivan J,et al. Topotecan in pediatric patients with recurrent and progressive solid tumors:A Pediatric Oncology Group phaseⅡstudy , J Pediatr Hematol Oncol,1998,20(4):315-318
8 Saylors RL ,Stine KC,Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phaseⅡstudy, J Clin Oncol, 2001,19(15):3463-3469
9 Athale UH,Stewart C, Kuttesch JF, et al. PhaseⅠstudy of combination topotecan and carboplatin in pediatric solid tumors, J Clin Oncol, 2002, 20(1):88-95
10高解春,金百祥,Ⅲ、Ⅳ期神经母细胞瘤的外科处理,中华小儿外科杂志,1995,16:70
11高解春,小儿晚期恶性肿瘤延期和二次手术的指征和时机,中华小儿外科杂志,1995,16:295
12江启俊,外科治疗神经母细胞瘤的世纪回顾及展望,中华小儿外科杂志,2000,21:137
13 Meller S, Targeted radiotherapy for neuroblastoma, Arch Dis Child, 1997,77(5):389-391
14 Sehmidt M, Simon T, Hero B, et a1.Is there a benefit of131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma?A retrospective evaluation of the German Neuroblastoma Trial NB97 and implications for the German Neuroblastoma Trim, NB 2004 Nuklearmedizin, 2006,45(4):145-151
15 Matthay KK, Tan JC, Villahlanca JG, et a1.PhaseⅠdose escalation ofIodine-131I-metaiodobenzylguanidine with myeloablative chemother- apy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study, J Clin Oncol , 2006,24(3):500-506
16 Garaventa A, Gambini C, Villavecchia Gm ,et al. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodohanzylguanidine, Cancer , 2003,97(5):1332-1338
17 Weiss B,Vora A, Huberty J, et a1. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma, J Pediatr Hematol Oncol, 2003,25(7):543-547
18 Osenga KL, Hank JA, Albertini MR,et a1. A phase I clinical trial of the hul4.18-IL2(EMD 273063)as a treatment for chil dren with refractory or recurrent neuroblastoma and melanoma:a study of the Children’s Oncology Group, Clin Cancer Res , 2006,12(6):1750-1759
19 Gilman AI, Matthay KK,et a1. Phase I study of chl4.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue:a report from the Children’s Oncology Group, J Clin Oncol, 2009, 27(1):85-91
20 Verdeguer A, Munoz A, Canete A, et al . Long-term results of high-dose chemotherapy and autologousstem cell rescue forhigh-risk neuroblastoma patients: a report of the Spanish working party for BMT in children (Getmon) ,Pediatr Hematol Onenl , 2004, 21:495-504
21 Berthold F, Boos J, Burdach S,et a1.Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance hemotherapy as consolidation treatment in patients with high-risk neuroblastorna : a randomised controlled trial, theLancet Oncol, 2005,6:649-658
22 Philip T, Ladenstein R, Lasset C, et al 1070 myeloablative megatherapy procedurea followed by stem cell rescue for neuroblastoma:17 years of European experience and conclusions.European Group for Blood andMarrow Transplant Registry Solid Tumour Working Party, Eur J Cancer,1997, 33:2130-2135
23 Zage PE, Kletzel M, Murray K, et al. Outcomes of the POG 9340/ 9341/9342 trials for children with high-risk neuroblastoma: a report from the Children′s Oncology Group, Pediatr Blood Cancer, 2008,51(6):747-753
24 Imaizum iM, W atanabe A, Kikuta A, et al. Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation:a retrospective analysis from the Tohoku Neuroblastoma Study Group, Tohoku J Exp Med, 2001,195(2):73-83
25 Stram Do,Matthay KK O, Leary M, et al.Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma:a report of two concurrent Children's Cancer Group studies,J CIin Oncol, 1996,14:2417-2426
26 Ladenstein R, Lasset C,Hartmann O,et a1. Comparison of auto versus allografting as consolidation of primary treatments in advanced neurob- lastoma over one year of age at diagnosis: report from theEuropean Groupfor Bone MarrowTransplantation, Bone MarrowTransplant,1994,14:37-46
27 Samuels HL, Bitran JD, High-dose intravenous melphalan:a review, J Clin Oncol, 1995, 13:1786 -1799
28 Donovan J,Temel J, Zuckel'manA, et al. CD34 selectionas a stem cell purging strategy for neuroblastoma: preclinical and clinical studies, Med Pediatr Oncol,2000,35:677-682
29 Handgretinger R,Larlg P,Ihm K, et al. Isolation and transplantation of highly purified autologous peripheral CD34(+)progenitor cells:purging efficacy, hematopoietie reconstitution and long-term outcome in children with high-risk neuroblastoma,Marrow Transplant, 2002,29:731-736
30陈静,沈小钰,汤静燕等,儿童晚期神经母细胞瘤自身造血干细胞移植疗效评估,中国循证儿科杂志, 2009,4( 2)118-122
31 George RE, Li S,Medeiros-Nancarrow C,et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell supported transplantation: long-term survival update, J ClinOnco, 2006,24:2891-2896
32 yon AIlmen ,DtGrupp S,Diller L, et a1. Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence and transplant, J Pediatr surg , 2005, 40:936-941
33 Jing w ,Orentas RJ, Johnson BD, Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem eell trapsplantation using a hovel mouse tumor vaccine, Biol Blood MarrowTransplant, 2007,13:277-292
34 Toren A, Nagler A, Rozenfeld-Granot G, et a1.Amplification of immunologieal functions by subeutaneoua injection of intermediate dose interleukin-2 for 2 years after autologous stem cell transplantation in children with stage IV neumblastoma.Transplantation, 2000, 70:1 100-1 104
35 Wassberg E, Christofferson R.Angiostatic treatment of neuroblastoma,Eur J Cancer, 1997, 33:2-20
36 Frost JD, Hank JA, Reaman GH,et al. A phase I/BI trial of murine monoclonal anti-GD2 antibody plus interleukin-2 in children with refractory neuroblastoma:A report of the Children′s Cancer Group, Cancer,1997,80(2):317-333
37 Niethammer D, Hemdgnetinger. Clinical strategies for the treatment of neuroblastoma, Eur J Cancer,1995,31:568 -571
38 Valteau-Couanet D, Leboulaire C,Maincent K, et a1.Dendritie cells for NK/ LAK activation:rationale for multicellular immlunotherapy in neurob-lastoma patients, Blood, 2002,100:255-256
39 Reynolds CP, Detection and treatment of minimal residual disease in high-risk neuroblastoma, Pediatr Transplant, 2004, 8:56-66
40 Katzenstein HM, Rademaker AW, Senger C, et al Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden,Clin Cancer Res,1999,5(12):4273-4278
41 Shusterman S,Grupp SA,Barr R,et al The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth,especially in the setting of subclinical disease, Clin Cancer Res,2001,7(4):977-984
42 Kohler JA, Imeson J, Ellershaw C, et al. A randomized trial of 13-cis retinoic acid in childrenwith advanced neuroblastoma after high-dose therapy, Br J Cancer , 2000, 83:1124-1127
43 Bown N, Lastowska M, Cotterill S,et al. 17q gain in neuroblastoma predicts adverse clinical outcome.U.K Cancer Cytogenetics Group and the U.K.Children’s Cancer Study Group. Med Pediatr Oncol, 2001, 36(1)14-19
44 Mihaila D, Ap rodu G, Ionescu C, et al. Limitations in the histopathologic diagnosis and prognosis of neuroblastoma,RevMed ChirSoc Med Nat Lasi, 2003,107(4):834-840
45 Zumkeller W, Schwab M, Insulin-like growth factor system in neuroblastoma tumorigenesis and apoptosis perspectives, Horm Metab Res, 1999, 31:138 -141
46 Donfrancesco A , Deb G , DE Sl, et al. Role of deferoxamine in tumor therapy, Acta Haenatol,1996,95:66 -69